Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 20;15(2):464–476. doi: 10.1111/cts.13164

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Janssen Research & Development. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Predicted median plasma concentration profiles for CYP enzyme substrates in patients with IMID before and after anti‐IL‐6 treatment. Predicted median plasma concentration‐time profiles for midazolam, omeprazole, S‐warfarin, and caffeine in patients with SLE, UC/CD, and T1D before anti‐IL‐6 treatment, and in healthy subjects (after anti‐IL‐6 treatment condition). CD, Crohn’s disease; IMID, immune‐mediated inflammatory disease; SLE, systemic lupus erythematosus; T1D, type 1 diabetes; UC, ulcerative colitis